timothy sykes logo

Stock News

TG Therapeutics Shares Surge: What’s Next?

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Ellis Hobbs Fact-checked by Matt Monaco
TG Therapeutics Shares Surge: What’s Next? Thumbnail

TG Therapeutics Inc.’s stocks are likely trading higher due to positive developments from critical news articles, such as the company’s recent successful clinical trial results or significant regulatory approvals. On Friday, TG Therapeutics Inc.’s stocks have been trading up by 9.66 percent.

TG Therapeutics (TGTX) is causing waves in the stock market with its unexpected surge. Multiple news outlets have reported positive developments, drawing attention from investors and analysts alike.

Market Drivers and Latest Developments:

  • TG Therapeutics projected its full-year 2025 revenue at $540M, surpassing analyst expectations of $534.45M.
  • The company announced significant Q4 earnings growth, reporting $108.2M in revenue, outpacing forecasts of $100.67M.
  • B. Riley raised TGTX’s price target from $38 to $53, maintaining a positive outlook with a buy recommendation.
  • The firm’s recent earnings turnaround showcases a net gain of $0.15 per diluted share, contrasting with the loss reported last year.
  • TG Therapeutics shared a robust cash position and promising future projections, contributing to over an 18% increase in stock value.

Candlestick Chart

Live Update At 17:20:37 EST: On Friday, March 07, 2025 TG Therapeutics Inc. stock [NASDAQ: TGTX] is trending up by 9.66%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Earnings Insight: TG Therapeutics on the Upswing

As traders navigate the volatile world of markets, it’s important to maintain a disciplined approach. Acting on impulse can lead to unnecessary risks and potential losses. As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.” Instead of hastily making decisions based on fear of missing out, successful traders analyze thoroughly and wait patiently for the right opportunities, ensuring their strategies are well informed and deliberate.

Analysts and investors are abuzz with the latest earnings report from TG Therapeutics, highlighting a remarkable turnaround. The company reported net income, contrasting last year’s losses, coupled with robust revenue growth. The successful adoption of BRIUMVI for multiple sclerosis significantly contributed to their Q4 earnings, underscoring the company’s strategic direction and market adaptability.

A detailed look into their financial strength reveals strengths and areas of concern. With a high gross margin of 88.3%, TG Therapeutics shows efficiency in cost management. However, profitability metrics like the EBIT margin and pretax profit margin highlight challenges. The company scores an impressive total asset turnover, indicating effective usage of resources.

More Breaking News

Recent trading data reveals an upward trajectory for their stock. Starting the month at around $30, TGTX trading soared to close at $38.44 on Mar 7, 2025. Midday fluctuations reflect investor confidence fueled by upbeat earnings reports and market forecasts.

Interpreting the Buzz: Stock Movement Explained

Positive sentiment ripples through the market amid TG Therapeutics’ strong revenue forecasts and investor confidence in its future. The promising expansion of BRIUMVI not only improved revenues but sparked interest in their diverse research pipeline. B. Riley’s new target price aligned with positive earnings forecasts further inflates investor enthusiasm.

From a financial metrics perspective, TG Therapeutics’ current ratio and quick ratio position it well to tackle short-term obligations without cash flow constraints. Still, a watchful eye on debt levels remains prudent, as they maintain considerable leverage.

The rise in share price can also be attributed to the market’s positive response to their ambitious 2025 revenue projections—indicative of the company’s strategic foresight and robust cash reserves. Despite hurdles, these elements contribute to the stock’s meteoric rise.

Concluding Market Insights

TG Therapeutics has emerged as a phoenix in the biotech sphere. Driven by strategic growth in their multiple sclerosis portfolio and backed by financial acumen, the company has reversed past challenges. Trader confidence swells on the back of financial metrics, supportive forecasts, and deft market maneuvering. As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” This mindset will be crucial moving forward, as vigilance over leverage strategies and focus on sustainable growth will be pivotal. As the stock continues its upward climb, eyes remain on upcoming quarterly updates and market shifts. The tale of TGTX is a compelling study of risk, resilience, and responsive strategy in today’s volatile market.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”